These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15934956)

  • 1. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism.
    González EA; Al-Aly Z; Martin KJ
    Semin Dial; 2005; 18(3):171-4. PubMed ID: 15934956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [K/DOQI clinical practice guidelines for bone metabolism and disease in CKD].
    Sakaguchi T; Akizawa T
    Clin Calcium; 2004 Sep; 14(9):9-14. PubMed ID: 15577103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
    Bailie GR; Massry SG;
    Pharmacotherapy; 2005 Dec; 25(12):1687-707. PubMed ID: 16305288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outlines of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease].
    Orita H; Akizawa T
    Clin Calcium; 2004 May; 14(5):693-7. PubMed ID: 15577029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
    Ito H; Kinugasa E
    Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D; Tatematsu M
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
    Yano S
    Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications.
    Uribarri J;
    Semin Dial; 2004; 17(5):349-50. PubMed ID: 15461740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
    Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified.
    Ix JH; Quarles LD; Chertow GM
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):337-9. PubMed ID: 16932455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
    Kumar N; Lindberg J; David K; Morris J; Menoyo J
    Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing bone parameters in dialysis patients: international guideline conflicts.
    Faull RJ
    Semin Dial; 2007; 20(3):191-4. PubMed ID: 17555479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL; Hristova M; Ho LT; Sprague SM
    Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.